TrivarX secures key partner ahead of Stabl-lm Phase I study

Detailed summary

TrivarX has appointed Emeritus Research to conduct a planned Phase I healthy volunteer study of its Stabl-Im imaging technology. ... Read More The post TrivarX secures key partner…

TrivarX is building its team of partners to advance its Phase I study of Stabl-lm. Pic: Getty Images.

Special Report: TrivarX has appointed Emeritus Research to conduct a planned Phase I healthy volunteer study of its Stabl-Im imaging technology.

The planned study is to be carried out at Emeritus’ clinical research facility in Melbourne.

TrivarX (ASX:TRI) said Emeritus was selected for its established clinical trial infrastructure, experienced research personnel and participant recruitment capabilities.

The Australian clinical research network and its affiliates have more than 25 years of experience conducting trials across a broad range of therapeutic areas.

This builds on TRI’s recent appointment of pharmaceutical manufacturing specialist Syntro Health for investigational product preparation activities.

TRI now has both key delivery partners in place as it advances clinical, technical and operational preparations.

Stabl-Im is TRI’s stable isotope-based imaging development platform, which aims to improve the detection and characterisation of cancer, initially focusing on brain tumours and brain metastases.

The platform uses controlled enrichment of plasma with deuterium, a non-radioactive stable isotope of hydrogen, to investigate whether metabolic differences between healthy and cancerous tissue can be detected using magnetic resonance imaging (MRI).

Opening of the article, excerpted from Stockhead. To read the rest, open the article on the publisher's site.